| Product | Indication | Dosage form | Strength |
|---|---|---|---|
| Nabilone * | Antiemetic | Tablets | 1 mg |
| Ondansetron | Nausea & vomiting | Film-coated tablets | 4 and 8 mg |
| Ondansetron | Nausea & vomiting | Orodispersable tablets | 4 and 8 mg |
[*] Differentiated product
[**] Opioid
Listed products protected by valid patents are developed solely for purposes related to the development, preparation and submission of information to obtain a Marketing Authorisation. In particular these products are under development for uses related to the activities stated in Art. 10.6 of Directive 2001/83/EC amended by the Directive 2004/27/EC of the European Parliament and of the Council of 31 March 2004, i.e. activities carried out to obtain a Marketing Authorisation. None of the products are offered for sale or supplied to countries in which they could be in conflict with valid patents.
© Neuraxpharm / LESVI. All rights reserved.